09:00

Welcome and introduction

Frédéric Lioté (France), Fernando Perez-Ruiz (Spain)

MORNING - SESSION 1

Chairs: Leo Joosten (The Netherlands), Hang-Korng Ea (France)

09:05

Introduction to IL-1 Keynotes

Leo Joosten (The Netherlands), Hang-Korng Ea (France)

09:15

From IL-1 discovery to novel therapeutic strategies in diseases

Charles Dinarello (United States)

09:45

Induction of trained immunity: role of IL-1 family of cytokines

Mihai Netea (The Netherlands)

MORNING - SESSION 2

11:00

How IL-1 started 2 revolutions: innate immunity and immunometabolism

Luke O’neill (Ireland)

11:45

Gene regulation, non-coding RNA landscape in IL-1 mediated inflammation

Musa Mhlanga (The Netherlands)

AFTERNOON - SESSION 1

Chairs: Jessica Bertrand (Germany), Hervé Kempf (France)

13:30

Bones and Eggshells: Mineralization of extracellular matrix fiber networks in 3D by X-ray and electron tomography

Marc McKee (Québec - Canada)

14:00

Abnormal tooth mineralization in the context of rare disorders

Catherine Chaussain (France)

14:30

New insights into the key role played by inflammation in chronic kidney disease-induced cardiovascular calcifications

Lucie Hénaut (France)

15:00

The potential of a novel cartilage-on-chip system to study human cartilage calcification

Carlo Alberto Paggi (The Netherlands)

AFTERNOON - SESSION 2

Chairs: Michael Doherty (UK), Fernando Perez-Ruiz (Spain)

15:45

Gout and cardiovascular issues: an update

Claudio Borghi (Italy)

16:15

Oral communications (6 min + 3 min Q&A) - Session 1

Treat to Target in gout yields superior outcomes compared to Treat to Avoid Symptoms approach. Results from Gout TrEatment Strategy (GO TEST) OVERTURE trial

Anusha Moses (The Netherlands)

Differences in the inflammatory proteome of gout patients during flare, inter-critical and T2T conditions reveals new disease biomarkers

Brenda Kischkel (The Netherlands)

Correlation of circulatory mineralization factors with alkaline phosphatase activity upon aging in mice and human

Flora Szeri (Hungary)

Risk of cardiovascular events after first gout flare consultation in primary care: a self-controlled case series analysis using UK primary-care, hospitalisation, and mortality data.

Edoardo Cipolletta (UK)

Risk of cardiovascular events in patients with gout starting urate-lowering therapy with or without flare prophylaxis with colchicine: an emulated target trial using english primary-care, hospitalisation, and mortality data

Edoardo Cipolletta (UK)

Runt-related Transcription Factor (RUNX) 1 activation by Monosodium Urate Crystals influences the production of inflammatory cytokines in human monocytes

Laura M. Merlo Pich (The Netherlands)

Differential regulation of pyrophosphate metabolism in calcified and non-calcified cartilage and synovium of osteoarthritis patients

Sina Stücker (Germany)

Elucidating the pathogenicity of calciprotein particles in osteoarthritis

R.H.M.J. Stassen (The Netherlands)

08:45

Introduction

Frédéric Lioté (France), Fernando Perez-Ruiz (Spain)

MORNING - SESSION 1

Chairs: Tania Crisan (Romania), Sonia Nasi (Switzerland)

09:00

How does “Particulates and NLRP3 inflammasome activation” sound ?

Tony Merriman (New Zealand)

09:30

Fasting and crystal-induced inflammation

Hang-Korng Ea (France)

10:00

PPi homeostasis and human diseases

Christophe Duranton (France)

MORNING-SESSION 2

Chairs: Robert Terkeltaub (United States), Alexander So (Switzerland)

11:00

SGLT2i and gout

Hyon Choi (United States)

11:30

Oral communications (6 min + 3 min Q&A) - Session 2

Inhibition of urate transporters and insulin-activated urate transport by SGTL2 inhibitors

David B. MOUNT (United States)

Intermittent fasting and spermidine reduce inflammation induced by monosodium urate (MSU) and calcium pyrophosphate dihydrate (CPPD) crystals

Nghia Pham (France)

Genetic loci that affect urate levels but not gout risk – an apparent discordance between urate and gout genetics

Riku Takei (United States)

Ionic Profile of Synovial Fluids in Gout, Calcium Pyrophosphate Crystal Deposition Disease and Osteoarthritis

Mete KAYATEKIN (France)

Prediagnostic proteomics of gout: prospective cohort study of 48,898 men and women

Natalie McCormick (United States)

Transcriptomic analysis reveals a proinflammatory signature in Gout and Hyperuricemia Introduction

Valentin Nica (Romania)

Evaluation of urate monitoring in gout: an extension of the GoutSMART supported self-management trial

Philip L. RICHES (UK)

AFTERNOON - SESSION 1

Chairs: Hyon Choi (United States), Hang-Korng Ea (France)

13:30

Which crystals within wall arteries? View point of a radiologist

Fabio Becce (Switzerland)

14:00

Mortality in gout: epidemiology

Matts Dehlin (Sweden)

14:30

The gut in gout

Robert Terkeltaub (United States)

AFTERNOON - SESSION 2

Chairs: Frédéric Lioté (France), Fernando PEREZ-RUIZ (Spain)

15:15

Oral communications (6 min + 3 min Q&A) - Session 3

“Gout remission” after 1-year of intensive urate-lowering with pegloticase

Brian Lamoreaux (United States)

Safety & efficacy of SEL-212 in patients with gout refractory to conventional treatment: outcomes from two randomized, double blind, placebo-controlled, multicenter phase 3 studies

Herbert S.B. Baraf (United States)

Urate-induced immunometabolic adaptations of myeloid cells

Georgiana Cabau (Romania)

Assessment of the inflammatory profile expressed in asymptomatic hyperuricemia with sonographic deposits, including a comparison with normouricemia and gout

Mariano Andrés (Spain)

Overlap of gout variants with Activity-By-Contact (ABC) enhancers in stimulated innate immune cells reveals CSF1 and CSF1R genes involved in the gout inflammation

Riku Takei (United States)

Prevalence and factors associated to calcium pyrophosphate arthritis (CPPA) in patients with gout

Fernando Perez-Ruiz (Spain)

A Comparative Analysis of Single-Energy CT and Dual-Energy CT in Detecting Crystal Deposits in Gout and Calcium Crystal Deposition Diseases

Fabio Becce (Switzerland)

Development of a Deep Learning Model for Automated Detection of Calcium Pyrophosphate Deposition on Hand Radiographs

Elisabeth Rosoux (Switzerland)

16:30

IL-6 pathway and crystal-induced arthritis

Augustin Latourte (France)

17:00

FAREWELL

Frédéric Lioté (France), Fernando Perez-Ruiz (Spain)